Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Graphene nanoplatelets products maker Directa Plus upgraded its guidance on revenue following good progress in the second half of the year amid new business wins.
The company said it was confident of achieving total revenues for the year ending 31 December 2020 of approximately €6.0 million, exceeding current consensus market expectations.
The upbeat outlook comes as the company continued to make 'good progress during the second half of 2020, with orders and agreements signed for the company's products and services across all verticals, Directa Plus added.
'This improvement in trading performance has been primarily driven by the sales of G+ enhanced face masks, including Co-Masks, which have proven very popular with both individual and corporate customers and have generated strong demand.'
At 9:13am: (LON:DCTA) Directa Plus Plc share price was 0p at 61p